Oruka Therapeutics (ORKA) Amortization of Deferred Charges (2019 - 2025)
Oruka Therapeutics' (ORKA) quarterly Amortization of Deferred Charges came in at $132000.0 in Q3 2025, up 116.39% year-on-year from $61000.0 in Q3 2024, and up 116.39% quarter-over-quarter from $61000.0 in Q3 2024.
Oruka Therapeutics (ORKA) Amortization of Deferred Charges (2019 - 2025) Analysis & Trends
Oruka Therapeutics' Amortization of Deferred Charges history runs 7 years deep, the most recent figure standing at $132000.0 for Q3 2025.
- On a quarterly basis, Amortization of Deferred Charges rose 116.39% year-over-year to $132000.0 in Q3 2025; TTM through Sep 2025 was $197000.0, a 131.76% increase from a year earlier, with the FY2023 full-year figure at $96000.0, up 2.13% from the prior year.
- Amortization of Deferred Charges climbed to $132000.0 in Q3 2025 per ORKA's latest filing, from $61000.0 in the prior quarter.
- Across five years, Amortization of Deferred Charges topped out at $132000.0 in Q3 2025 and bottomed at -$12000.0 in Q2 2024.
- The 5-year median for Amortization of Deferred Charges is $23000.0 (2021), against an average of $28875.0.
- Biggest YoY gain for Amortization of Deferred Charges was 134.62% in 2024; the steepest drop was 148.0% in 2024.
- Year by year, Amortization of Deferred Charges stood at $23000.0 in 2021, then grew by 4.35% to $24000.0 in 2022, then retreated by 16.67% to $20000.0 in 2023, then soared by 205.0% to $61000.0 in 2024, then surged by 116.39% to $132000.0 in 2025.
- Per Business Quant, the three latest ORKA Amortization of Deferred Charges figures stand at $132000.0 (Q3 2025), $61000.0 (Q3 2024), and -$12000.0 (Q2 2024).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,222.41 Bn | 67,222.13 Bn | - |
| 2 | Nanobiotix | 1,909.44 Bn | 1,909.38 Bn | - |
| 3 | Akari Therapeutics | 989.71 Bn | 989.71 Bn | - |
| 4 | BeOne Medicines | 471.12 Bn | 466.33 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.84 Bn | 114.59 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.89 Bn | 61.14 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.74 Bn | 62.74 Bn | - |
| 8 | Argenx Se | 55.83 Bn | 50.64 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.34 Bn | 34.34 Bn | 959.66 Mn |
| 10 | Oruka Therapeutics | 957.95 Mn | 126.79 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 132,000.00 |
| Sep 30, 2025 | 132,000.00 |
| Sep 30, 2024 | 61,000.00 |
| Sep 30, 2024 | 61,000.00 |
| Jun 30, 2024 | -12,000.00 |
| Jun 30, 2024 | -12,000.00 |
| Mar 31, 2024 | 16,000.00 |
| Mar 31, 2024 | 16,000.00 |
| Dec 31, 2023 | 20,000.00 |
| Dec 31, 2023 | 20,000.00 |
| Sep 30, 2023 | 26,000.00 |
| Sep 30, 2023 | 26,000.00 |
| Jun 30, 2023 | 25,000.00 |
| Jun 30, 2023 | 25,000.00 |
| Mar 31, 2023 | 25,000.00 |
| Mar 31, 2023 | 25,000.00 |
| Dec 31, 2022 | 24,000.00 |
| Dec 31, 2022 | 24,000.00 |
| Sep 30, 2022 | 24,000.00 |
| Sep 30, 2022 | 24,000.00 |